TrialClinical cancer research : an official journal of the American Association for Cancer Research2019

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.

Jean-Christophe Pignon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.